Obesity may affect immune drug dosing – study seeks answers

NCT ID NCT04818177

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates how obesity affects the way the body processes intravenous immune globulin (IVIG), a treatment for immune deficiencies. Researchers measured body composition and blood levels of IVIG in 40 obese and normal-weight patients to find the best dosing strategy. The goal is to reduce side effects from overdosing and ensure effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
intravenous immune globulin (IVIG)
What this could lead to
If successful, this study could lead to better dosing guidelines for IVIG in obese patients, reducing side effects and improving treatment outcomes.
What could go wrong
This is a small, observational study with only 40 participants, so results may not apply to all patients. It does not test a new treatment, only refines existing dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Robert Wood Johnson University Hospital Somerset

    Somerville, New Jersey, 08876, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.